8-K: InfuSystem and Sanara MedTech Partner to Distribute ChemoMouthpiece in the U.S.

InfuSystem and Sanara MedTech have entered an exclusive distribution agreement with ChemoMouthpiece, LLC for its oral cryotherapy device in the United States.

Summary

• InfuSystem Holdings, Inc. and Sanara MedTech Inc. have partnered to exclusively distribute the ChemoMouthpiece, an oral cryotherapy device, in the United States.
• The distribution will be managed through SI Healthcare Technologies, a joint venture between InfuSystem and Sanara.
• Sanara has made a $5 million investment for a 6.6% ownership stake in ChemoMouthpiece.
• SI Technologies will purchase ChemoMouthpiece kits at a fixed price and pay a royalty on net revenues.
• The ChemoMouthpiece is a 510(k) cleared device designed to reduce oral mucositis, a common side effect of chemotherapy.
• The estimated market size for oral mucositis treatments exceeds $600 million annually, with 500,000 to 1,000,000 patients affected in the U.S.
• SI Technologies plans to distribute the product through InfuSystem's existing oncology sales team, targeting approximately 3,000 cancer centers.
• SI Technologies has a purchase option to acquire the U.S. business of ChemoMouthpiece, including all related intellectual property, expiring on January 31, 2029.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook due to the strategic partnership, the potential market size, and the clinical validation of the product. The new CPT code is also a positive factor.

Positives

• The exclusive distribution agreement provides InfuSystem and Sanara with access to a significant market opportunity.
• The ChemoMouthpiece is a clinically validated product with FDA 510(k) clearance.
• The product addresses a significant unmet need for cancer patients suffering from oral mucositis.
• The new CPT code for oral cryotherapy devices may facilitate reimbursement and adoption.
• InfuSystem's existing oncology sales team provides a ready-made distribution channel.
• The purchase option provides a potential future growth opportunity for SI Technologies.

Risks

• The success of the distribution agreement depends on the market adoption of the ChemoMouthpiece.
• There are risks associated with the commercialization of new medical devices.
• The company's ability to generate estimated potential revenue amounts under new or existing contracts is not guaranteed.
• The company is subject to risks related to changes in third-party reimbursement processes and changes in law.
• The company is subject to global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, and systemic pressures in the banking sector.

Future Outlook

The companies expect the distribution agreement to bring the ChemoMouthpiece to thousands of cancer patients, potentially reducing the incidence and severity of oral mucositis. ChemoMouthpiece plans to publish studies reinforcing the efficacy of their product.

Management Comments

• Richard DiIorio, InfuSystem's CEO, stated that the partnership with Sanara aims to deliver proprietary products to patients and that the agreement will allow them to offer the Chemo Mouthpiece.
• Ron Nixon, Sanara's CEO, noted that oral mucositis is a debilitating condition and that the ChemoMouthpiece is a clinically validated product that can bring relief to affected patients.
• David Yoskowitz, ChemoMouthpiece's President and CEO, expressed confidence that InfuSystem's experienced oncology team will accelerate the uptake of the Chemo Mouthpiece.

Industry Context

This announcement reflects a growing trend in the healthcare industry towards innovative solutions for managing side effects of cancer treatments. The partnership leverages the strengths of InfuSystem's distribution network and Sanara's expertise in medical technology to bring a new product to market.

Comparison to Industry Standards

• The oral mucositis market is a significant area of unmet need, with several companies developing various solutions.
• While specific competitors are not named, the market includes companies offering cryotherapy, laser therapy, and other pharmaceutical interventions.
• The ChemoMouthpiece's 510(k) clearance and the new CPT code for oral cryotherapy devices position it well for potential market adoption.
• The partnership between InfuSystem and Sanara leverages existing distribution channels, which is a common strategy for medical device companies.

Related Party Transactions

• Sanara's $5 million investment in ChemoMouthpiece is a related party transaction.
• The distribution agreement between SI Technologies (a joint venture of InfuSystem and Sanara) and ChemoMouthpiece is a related party transaction.

Stakeholder Impact

• Shareholders of InfuSystem and Sanara may benefit from the potential revenue growth and market expansion.
• Cancer patients may benefit from the availability of a new treatment option for oral mucositis.
• Healthcare providers may benefit from a new tool to manage a common side effect of chemotherapy.
• ChemoMouthpiece will benefit from the distribution partnership and investment.

Next Steps

• SI Technologies will begin marketing and distributing the ChemoMouthpiece through InfuSystem's oncology sales team.
• ChemoMouthpiece plans to publish studies reinforcing the efficacy of their product.

Key Dates

Keywords

ChemoMouthpiece, oral cryotherapy, oral mucositis, cancer, oncology, distribution agreement, medical device, cryotherapy, Sanara MedTech, InfuSystem, SI Technologies